Published 2012 | Version v1

Publication Metadata-only

Updated safety result of a large Italian early access program (EAP) with cabazitaxel plus prednisone (CbzP) in metastatic castration-resistant prostate cancer (mCRPC) patients who progressed during or after docetaxel (D) therapy.

Creators: Bracarda, S; Di Lorenzo, G; Gasparro, D; Marchetti, P; BOCCARDO, FRANCESCO; Martoni, A; Carteni, G; Fornarini, G; Baldazzi, V; Dogliotti, L; Messina, C; Sisani, M.

Others:: Bracarda, S; Di Lorenzo, G; Gasparro, D; Marchetti, P; Boccardo, Francesco; Martoni, A; Carteni, G; Fornarini, G; Baldazzi, V; Dogliotti, L; Messina, C; Sisani, M.

Style

An error occurred while generating the citation.

Additional details

Created:: April 14, 2023
Modified:: November 29, 2023